CN112424198A - 噻二嗪衍生物 - Google Patents

噻二嗪衍生物 Download PDF

Info

Publication number
CN112424198A
CN112424198A CN201980046660.4A CN201980046660A CN112424198A CN 112424198 A CN112424198 A CN 112424198A CN 201980046660 A CN201980046660 A CN 201980046660A CN 112424198 A CN112424198 A CN 112424198A
Authority
CN
China
Prior art keywords
disorder
disorders
disease
formula
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980046660.4A
Other languages
English (en)
Chinese (zh)
Inventor
I·雷德内克茨基
J·艾利斯
P·泰普克萨南伊
E·姚布隆考伊
E·加博尔
A·维赛格拉德
Z·内梅赛
G·I·勒韦
J·L·佩特罗
G·谢莱尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jirui Factory
Original Assignee
Jirui Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jirui Factory filed Critical Jirui Factory
Publication of CN112424198A publication Critical patent/CN112424198A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980046660.4A 2018-07-13 2019-07-12 噻二嗪衍生物 Pending CN112424198A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1800249 2018-07-13
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Publications (1)

Publication Number Publication Date
CN112424198A true CN112424198A (zh) 2021-02-26

Family

ID=89992726

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046660.4A Pending CN112424198A (zh) 2018-07-13 2019-07-12 噻二嗪衍生物

Country Status (23)

Country Link
US (2) US12194050B2 (https=)
EP (1) EP3820865A1 (https=)
JP (2) JP7440486B2 (https=)
KR (1) KR20210033003A (https=)
CN (1) CN112424198A (https=)
AR (1) AR115783A1 (https=)
AU (1) AU2019300515B2 (https=)
BR (1) BR112020027016A2 (https=)
CA (1) CA3104264A1 (https=)
CL (1) CL2021000081A1 (https=)
CO (1) CO2021001224A2 (https=)
CU (1) CU24622B1 (https=)
EA (1) EA202190246A1 (https=)
GE (2) GEAP202215558A (https=)
HU (1) HU231414B1 (https=)
IL (1) IL279939B2 (https=)
MX (1) MX2021000461A (https=)
MY (1) MY207757A (https=)
PE (1) PE20210465A1 (https=)
PH (1) PH12021550007A1 (https=)
SG (1) SG11202012769QA (https=)
TW (1) TWI827628B (https=)
WO (1) WO2020012423A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103191A4 (en) * 2020-02-14 2024-03-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
CN103443092A (zh) * 2011-02-03 2013-12-11 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CN105051024A (zh) * 2013-03-13 2015-11-11 鲁平有限公司 作为α7烟碱型乙酰胆碱受体的调节剂的吡咯衍生物
WO2017165256A1 (en) * 2016-03-22 2017-09-28 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
ES2274729B1 (es) 2005-11-11 2008-06-01 Consejo Superior Investig. Cientificas Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides.
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
CN103443092A (zh) * 2011-02-03 2013-12-11 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CN105051024A (zh) * 2013-03-13 2015-11-11 鲁平有限公司 作为α7烟碱型乙酰胆碱受体的调节剂的吡咯衍生物
WO2017165256A1 (en) * 2016-03-22 2017-09-28 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
CO2021001224A2 (es) 2021-02-17
HUP1800249A2 (en) 2020-01-28
US20210267993A1 (en) 2021-09-02
CA3104264A1 (en) 2020-01-16
US12194050B2 (en) 2025-01-14
IL279939A (en) 2021-03-01
IL279939B1 (en) 2024-09-01
BR112020027016A2 (pt) 2021-04-06
MX2021000461A (es) 2021-06-23
TWI827628B (zh) 2024-01-01
EA202190246A1 (ru) 2021-04-20
JP2024056879A (ja) 2024-04-23
WO2020012423A1 (en) 2020-01-16
CL2021000081A1 (es) 2021-10-29
EP3820865A1 (en) 2021-05-19
GEAP202215558A (en) 2022-07-25
PH12021550007A1 (en) 2021-09-20
CU20200109A7 (es) 2021-08-06
HU231414B1 (hu) 2023-08-28
JP2021529813A (ja) 2021-11-04
AU2019300515B2 (en) 2025-01-23
SG11202012769QA (en) 2021-02-25
TW202019431A (zh) 2020-06-01
AU2019300515A1 (en) 2021-02-11
MY207757A (en) 2025-03-17
CU24622B1 (es) 2022-09-08
US20250064823A1 (en) 2025-02-27
KR20210033003A (ko) 2021-03-25
PE20210465A1 (es) 2021-03-08
AR115783A1 (es) 2021-02-24
GEP20237459B (en) 2023-01-25
JP7440486B2 (ja) 2024-02-28
IL279939B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7094989B2 (ja) シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
KR101772834B1 (ko) 다환형 화합물 및 이의 사용 방법
US8309578B2 (en) Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US20250064823A1 (en) Thiadiazine derivatives
JP5363315B2 (ja) 新規ピペラジン、医薬組成物、およびその使用方法
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
JP7599411B2 (ja) 受容体相互作用タンパク質キナーゼ１阻害剤（ｒｉｐｋ１）としての１ｈ－インダゾールカルボキサミド
TW201125864A (en) Novel compounds as casein kinase inhibitors
US9802927B2 (en) Oxadiazine compounds and methods of use thereof
CN112823157A (zh) 螺色满衍生物
CN118338902A (zh) 吡咯并[2,3-b]吡啶PGDH抑制剂及制备和使用方法
TWI907472B (zh) 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の（１，４−ジアザ−ビシクロ［３．２．２］ノン−６−エン−４−イル）−ヘテロシクリル−メタノンリガンド
TW202017904A (zh) 經取代之（吖）吲哚衍生物
TW202035403A (zh) 作為ｇａｂａａ ａ５受體調節子的雙環衍生物
TWI915553B (zh) 新穎化合物、包含其之組成物以及相關製備方法及醫藥用途
KR20200112910A (ko) 도파민 d3 수용체 길항 작용을 갖는 축환 화합물
OA20785A (en) Thiadiazine derivatives
EA043926B1 (ru) Производные спирохромана

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20250829